Related Experiment Videos
[New substances in oncologic therapy]
Abstract:
After presentation of several important methodological problems in the development of new cytostatic agents, the newer substances adriamycin, the nitroso-urea derivatives, ICDT, diaminodichloro-cisplatinum, VP 16-213 and tamoxifen are briefly discussed with regard to their pharmacology and activity spectra. In this context adriamycin, diaminochloro-cisplatinum and VP 16-213 may be considered break-throughs in the field of therapeutic oncology. Finally, several newer drugs still in phase I studies are mentioned.
Insights
This study reviews new cytostatic agents, highlighting adriamycin, diaminodichloro-cisplatinum, and VP 16-213 as breakthroughs in cancer therapy. It also discusses methodological challenges and emerging drugs in early development.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Context:
- Challenges in developing novel cytostatic agents.
- Review of recent advancements in cancer therapeutics.
Purpose:
- To discuss methodological problems in developing new cytostatic agents.
- To review the pharmacology and activity spectra of newer substances.
- To identify breakthroughs in therapeutic oncology.
Summary:
- Adriamycin, diaminodichloro-cisplatinum, and VP 16-213 represent significant advancements in cancer treatment.
- The study examines nitroso-urea derivatives, ICDT, and tamoxifen.
- Emerging drugs currently in Phase I clinical trials are also mentioned.
Impact:
- Identifies key breakthroughs in cancer drug development.
- Provides a concise overview of promising new cytostatic agents.
- Highlights areas for future research in therapeutic oncology.